Neurocrine Biosciences Files 8-K

TL;DR

NBIX filed an 8-K on 10/31, but details are scarce in this snippet.

AI Summary

Neurocrine Biosciences, Inc. filed an 8-K on November 1, 2024, reporting an event on October 31, 2024. The filing is categorized under 'Other Events' and does not contain specific financial figures or transactional details within the provided text.

Why It Matters

This filing indicates a material event has occurred for Neurocrine Biosciences, requiring disclosure to investors. However, the specific nature of the event is not detailed in this excerpt.

Risk Assessment

Risk Level: low — The provided text is a standard SEC filing header and does not contain information that poses an immediate risk.

Key Players & Entities

• NEUROCRINE BIOSCIENCES INC (company) — Registrant
• 0000914475-24-000214 (document_id) — Accession Number
• October 31, 2024 (date) — Earliest event reported
• November 1, 2024 (date) — Filing date
• San Diego, California (location) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value NBIX Nasdaq Global Select Mar
• $300.00 million — GS&Co."), to repurchase an aggregate of $300.00 million (the "Repurchase Price") of shares of t

Filing Documents

• nbix-20241031.htm (8-K) — 21KB
• nbix-20241031_g1.jpg (GRAPHIC) — 18KB
• 0000914475-24-000214.txt ( ) — 190KB
• nbix-20241031.xsd (EX-101.SCH) — 2KB
• nbix-20241031_lab.xml (EX-101.LAB) — 21KB
• nbix-20241031_pre.xml (EX-101.PRE) — 12KB
• nbix-20241031_htm.xml (XML) — 3KB

01. Other Events

Item 8.01. Other Events On October 31, 2024, Neurocrine Biosciences, Inc. ("Neurocrine Biosciences" or the "Company") entered into an accelerated share repurchase ("ASR") transaction under an agreement (the "ASR Agreement") with Goldman Sachs & Co. LLC ("GS&Co."), to repurchase an aggregate of $300.00 million (the "Repurchase Price") of shares of the Company's common stock, par value $0.001 per share (the "Common Stock"). The ASR transaction is being completed pursuant to a previously announced $300.00 million share repurchase program authorized by the Company's Board of Directors. Under the terms of the ASR Agreement, on November 4, 2024, Neurocrine Biosciences will pay the Repurchase Price and receive Common Stock with an aggregate value of 80% of the Repurchase Price based on the closing share price of the Common Stock on October 31, 2024. The total number of shares to be repurchased under the ASR Agreement will be based on volume-weighted average prices of the Common Stock during the term of the ASR transaction less a discount and subject to adjustments pursuant to the terms and conditions of the ASR Agreement. Upon final settlement of the ASR transaction, Neurocrine Biosciences may be entitled to receive additional shares of Common Stock from GS&Co. or, under certain circumstances specified in the ASR Agreement, Neurocrine Biosciences may be required to deliver shares of Common Stock or make a cash payment, at its option, to GS&Co. The ASR Agreement contains provisions customary for agreements of this type, including provisions for adjustments to the transaction terms, the circumstances generally under which the ASR transaction may be accelerated, extended or terminated early by GS&Co., and various acknowledgments, representations and warranties made by the parties to one another. The ASR transaction is scheduled to terminate in the first quarter of 2025.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NEUROCRINE BIOSCIENCES, INC. Dated: November 1, 2024 /s/ Darin M. Lippoldt Darin M. Lippoldt Chief Legal Officer